These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 808056)

  • 21. Subunit structure of cholera toxin.
    Lönnroth I; Holmgren J
    J Gen Microbiol; 1973 Jun; 76(2):417-27. PubMed ID: 4198716
    [No Abstract]   [Full Text] [Related]  

  • 22. Cholera toxin and toxoid.
    Ungar J; Stanić M; Chariatte N; Varallyay SJ
    Prog Immunobiol Stand; 1971; 5():348-9. PubMed ID: 4660540
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunoglobulins in bile and serum of the rabbit associated with protection after Vibrio cholerae infection and vaccination.
    Rijpkema SG; Jansen WH; Gielen H; Guinée PA
    Microb Pathog; 1987 Nov; 3(5):365-75. PubMed ID: 2462153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune response of the intestinal mucosa to cholera toxoid.
    Pierce NF; Sack RB
    J Infect Dis; 1977 Aug; 136 Suppl():S113-7. PubMed ID: 894085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits.
    Eko FO; Schukovskaya T; Lotzmanova EY; Firstova VV; Emalyanova NV; Klueva SN; Kravtzov AL; Livanova LF; Kutyrev VV; Igietseme JU; Lubitz W
    Vaccine; 2003 Sep; 21(25-26):3663-74. PubMed ID: 12922096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of Vibrio cholerae O1 fimbriae in animal and human cholera.
    Ehara M; Ichinose Y; Iwami M; Utsunomiya A; Shimodori S; Kangethe SK; Neves BC; Supawat K; Nakamura S
    Microbiol Immunol; 1993; 37(9):679-88. PubMed ID: 7505875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of the vibriocidal antibody response to live oral cholera vaccines.
    Wasserman SS; Losonsky GA; Noriega F; Tacket CO; Castañeda E; Levine MM
    Vaccine; 1994 Aug; 12(11):1000-3. PubMed ID: 7975839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
    Stewart-Tull DE; Lucas C; Bleakley CR
    Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunity to cholera: relation of fraction II of type 2 cholera toxin to vibriocidal antibody.
    Kaur J; Burrows W
    J Bacteriol; 1969 May; 98(2):467-74. PubMed ID: 4977478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model.
    Roy N; Barman S; Ghosh A; Pal A; Chakraborty K; Das SS; Saha DR; Yamasaki S; Koley H
    FEMS Immunol Med Microbiol; 2010 Oct; 60(1):18-27. PubMed ID: 20528929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Possibility of purifying cholera toxin (choleragen) and its antibodies by an immunosorption method].
    Zakrevskii VI; Efremenko VI; Lobanov VV; Dolmatova LA
    Zh Mikrobiol Epidemiol Immunobiol; 1979 May; (5):30-4. PubMed ID: 452780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mouse vibriocidal antibody test: a method for monitoring the potency of cholera vaccines.
    Ford AW; Seagroatt V; Alterman L; Hayhoe J
    J Biol Stand; 1982 Jan; 10(1):47-57. PubMed ID: 7068688
    [No Abstract]   [Full Text] [Related]  

  • 33. The adjuvant effect of pertussis endotoxin protein in modulating the immune response to cholera toxoid in mice.
    Sultzer BM; Craig JP; Castagna R
    Dev Biol Stand; 1985; 61():225-32. PubMed ID: 2872108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A new vaccinating antigenic fraction obtained from "Vibrio cholerae" I.--Isolation and characterization of the new fraction (author's transl)].
    Dodin A; Wiart J
    Ann Microbiol (Paris); 1975 Jan; 126(1):39-44. PubMed ID: 811146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Utilization of serological methods in the retrospective diagnosis of cholera and in detecting vibrion carriers].
    Bunin KV; Firsanov VI; Kravtsov EG; Nechaeva IP; Efimov DD
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Oct; (10):98-101. PubMed ID: 1210898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of the scientific-methodologic basis for vaccine standardization using cholerogen-toxoid as a model].
    Sumarokov AA
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Nov; (11):32-40. PubMed ID: 1221699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a purified cholera toxoid. I. Purification of toxin.
    Rappaport RS; Rubin BA; Tint H
    Infect Immun; 1974 Feb; 9(2):294-303. PubMed ID: 4205945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The characteristics of the protectiveness of a preparation of Vibrio cholerae outer membrane based on the data from a study using the ligated intestinal loop].
    Urbanovich LIa; Sappo SG; Kolesnik RS; Golubinskiĭ EP; Markov EIu; Ganin VS; Ivanova TA
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (2):43-6. PubMed ID: 9245140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity.
    Yang JS; An SJ; Jang MS; Song M; Han SH
    PLoS One; 2019; 14(3):e0213507. PubMed ID: 30845262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Experimental justification for combined subcutaneous immunization against cholera and typhoid fever].
    Gapochko KG; Emel'ianova OV; Ziablitsev IF
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Jan; (1):85-9. PubMed ID: 6702364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.